United Therapeutics Corp (UTHR) 129.37 $UTHR
United Therapeutics: Will It Pass Peers In 2015?
at Investor's Business Daily - Fri Dec 12, 5:11PM CST
Biomed company United Therapeutics is in a strong industry group, and that's a problem. United Therapeutics' (UTHR) three-year earnings growth rate is 26%, good enough for an EPS Rating of 89. However, in a leading group, "good enough" isn't good...
BIIB: 344.49 (+2.16), UTHR: 129.37 (-1.86), ALXN: 186.90 (-4.72), TEVA: 55.92 (-0.92), CELG: 114.49 (-2.25)
Can United Therapeutics find a remedy for recent resistance?
at Investor's Business Daily - Thu Dec 11, 10:48AM CST
Today we'll look at United Therapeutics (UTHR), which develops therapies to treat pulmonary arterial hypertension, cancer and some of the most complicated viral diseases. Key Fundamentals After a sharp decline in earnings growth for several quarters,...
UTHR: 129.37 (-1.86)
Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Thu Dec 11, 7:05AM CST
United Therapeutics (NASDAQ:UTHR) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $131.51 on volume of 653,000 shares, below average daily volume of 670,000. Based on a current price of $131.51, United Therapeutics is currently 3.7% above its average consensus analyst price target of $126.62. The stock should discover initial support at its 50-day moving average (MA) of $128.48 and subsequent support at its 200-day MA of $106.56.
UTHR: 129.37 (-1.86)
Stocks Fall To Session Lows: GoPro Gives Up More Ground
at Investor's Business Daily - Mon Dec 08, 12:25PM CST
Stocks were near session lows in early afternoon trading as oil prices fell hard again. The Nasdaq lost 0.5%, the S&P 500 fell 0.4% and the Dow Jones industrial average gave up 0.4% also. Nasdaq and NYSE volume was tracking slightly higher than...
AMBA: 46.33 (-1.64), GPRO: 60.52 (+0.47), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), UTHR: 129.37 (-1.86), MCD: 90.62 (-0.35), REGN: 416.44 (-7.91), CELG: 114.49 (-2.25)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.47 (+0.01), GILD: 104.13 (-0.18), UTHR: 129.37 (-1.86), GSK: 42.42 (-0.93), ARNA: 3.91 (-0.18)
Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 2:10PM CST
Actelion Ltd. (ALIOF) submitted a centralized marketing authorization application to the European Medicines Agency for its PAH candidate, Uptravi (selexipag).
BIIB: 344.49 (+2.16), UTHR: 129.37 (-1.86)
Stock Market Today: Top Biotech Is Near Buy Point
at Investor's Business Daily - Wed Nov 26, 4:40PM CST
Many leading stocks have risen out of buying range since a new market uptrend began last month, but a number are still working on bases. United Therapeutics (UTHR), which develops treatments for cardiovascular and infectious diseases as well as for...
UTHR: 129.37 (-1.86), GIII: 94.76 (-0.60), CAR: 58.65 (-3.55), CP: 176.41 (+1.71)
United Therapeutics Earnings In Retrospect: Down 3.9% in the Last 20 Days (UTHR)
Comtex SmarTrend(R) - Mon Nov 17, 3:24PM CST
20 days ago, on October 28th, 2014, United Therapeutics (NASDAQ:UTHR) reported its earnings. Analysts, on average, expected earnings of $2.75 per share on sales of $335.1 million. The company actually reported EPS of $3.91 on sales of $330.0 million, beating EPS estimates by $1.16 and missing revenue estimates by $5.2 million. Since the company's report, shares of United Therapeutics have fallen from $130.49 to $125.43, representing a loss of 3.9% in the past 20 days.
UTHR: 129.37 (-1.86)
United Therapeutics appoints Professor Katherine J. Klein to board
M2 - Thu Nov 13, 7:08AM CST
Biotechnology company United Therapeutics (NasdaqGS:UTHR) stated on Thursday that Professor Katherine J. Klein, PhD has been elected as an independent director to its board of directors with effect from 11 November 2014.
UTHR: 129.37 (-1.86)
Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors
PR Newswire - Thu Nov 13, 5:00AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today the appointment of Professor Katherine J. Klein, Ph.D., of The Wharton School of the University of Pennsylvania to its Board of Directors as an independent director. The appointment is effective as of November 11, 2014.
UTHR: 129.37 (-1.86), SCHW: 28.75 (-0.93)
United Therapeutics Earnings In Retrospect: Down 4.8% in the Last 13 Days (UTHR)
Comtex SmarTrend(R) - Mon Nov 10, 12:57PM CST
When United Therapeutics (NASDAQ:UTHR) reported earnings a week ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $2.75 on sales of $335.1 million. United Therapeutics actually reported earnings of $3.91 per share on sales of $330.0 million, beating EPS estimates by $1.16 and missing revenue estimates by $5.2 million. Shares of United Therapeutics have slipped from $130.49 to $124.21, representing a loss of 4.8%, since the company reported earnings 13 days ago.
UTHR: 129.37 (-1.86)
Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.69 (-0.77), WMGI: 28.30 (-0.10), CFN: 58.86 (-0.14), UTHR: 129.37 (-1.86), RCPT: 120.08 (-1.38), WMGIZ: 4.22 (-0.18)
Mid-Atlantic Claims $8.5 Billion Slice of $62 Billion North American Life Science Capital/MRO Investment Pie, an Industrial Info News Alert
Marketwired - Fri Oct 31, 5:15AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- There are more than 1,400 active reported Pharmaceutical-Biotech capital and maintenance (MRO) projects in North America, representing a total investment value (TIV) of nearly $62 billion. According to a recent analysis of Industrial Info's Pharmaceutical-Biotech Industry database, the Mid-Atlantic region is at the top of that investment, accounting for an $8.5 billion portion of that spending divided over 176 projects.
UTHR: 129.37 (-1.86)
Apple CEO publicly acknowledges that he's gay
By MAE ANDERSON - AP - Thu Oct 30, 6:59PM CDT
NEW YORK (AP) — Apple CEO Tim Cook's declaration that he's "proud to be gay" wasn't exactly news in Silicon Valley, where his sexual orientation was no secret. But advocates say that given Apple's immense reach and visibility, his coming-out could help change attitudes in workplaces across America.
UTHR: 129.37 (-1.86), AEO: 13.21 (+0.30), AAPL: 109.73 (-1.89)
United Therapeutics Sells Off On Good News - Why I Bought That Dip
DoctoRx - Seeking Alpha - Thu Oct 30, 2:52PM CDT
Background : The smallish biotech/biopharma company United Therapeutics (NASDAQ: UTHR ) is a favorite of mine on its own merits and as a takeover play. The company has a steadfast focus on the fatal orphan disease known as PAH (pulmonary arterial...
MDT: 72.52 (-1.25), GILD: 104.13 (-0.18), UTHR: 129.37 (-1.86), SUPN: 8.72 (+0.02), AMGN: 164.53 (-1.55), GSK: 42.42 (-0.93)
United Therapeutics Falls on Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:02AM CDT
United Therapeutics Corporation (UTHR) incurred a third-quarter loss of 53 cents per share, missing the Zacks Consensus Estimate by a wide margin.
LCI: 43.58 (-0.46), MDT: 72.52 (-1.25), UTHR: 129.37 (-1.86), NVS: 93.52 (-0.82)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 15.94 (+0.74), BIIB: 344.49 (+2.16), AMRN: 1.08 (+0.04), UTHR: 129.37 (-1.86), NLNK: 35.69 (+0.27)
SmarTrend Watching for Potential Rebound in Shares of United Therapeutics After 2.00% Loss
Comtex SmarTrend(R) - Tue Oct 28, 5:19PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $121.16 to a high of $131.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $127.76 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 129.37 (-1.86)
Watch for United Therapeutics to Potentially Rebound After Falling 2.00% Yesterday
Comtex SmarTrend(R) - Tue Oct 28, 5:18PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $121.16 to a high of $131.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $127.76 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 129.37 (-1.86)
United Therapeutics: Will It Pass Peers In 2015?
at Investor's Business Daily - Fri Dec 12, 5:11PM CST
Biomed company United Therapeutics is in a strong industry group, and that's a problem. United Therapeutics' (UTHR) three-year earnings growth rate is 26%, good enough for an EPS Rating of 89. However, in a leading group, "good enough" isn't good...
BIIB: 344.49 (+2.16), UTHR: 129.37 (-1.86), ALXN: 186.90 (-4.72), TEVA: 55.92 (-0.92), CELG: 114.49 (-2.25)
Can United Therapeutics find a remedy for recent resistance?
at Investor's Business Daily - Thu Dec 11, 10:48AM CST
Today we'll look at United Therapeutics (UTHR), which develops therapies to treat pulmonary arterial hypertension, cancer and some of the most complicated viral diseases. Key Fundamentals After a sharp decline in earnings growth for several quarters,...
UTHR: 129.37 (-1.86)
Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Thu Dec 11, 7:05AM CST
United Therapeutics (NASDAQ:UTHR) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $131.51 on volume of 653,000 shares, below average daily volume of 670,000. Based on a current price of $131.51, United Therapeutics is currently 3.7% above its average consensus analyst price target of $126.62. The stock should discover initial support at its 50-day moving average (MA) of $128.48 and subsequent support at its 200-day MA of $106.56.
UTHR: 129.37 (-1.86)
Stocks Fall To Session Lows: GoPro Gives Up More Ground
at Investor's Business Daily - Mon Dec 08, 12:25PM CST
Stocks were near session lows in early afternoon trading as oil prices fell hard again. The Nasdaq lost 0.5%, the S&P 500 fell 0.4% and the Dow Jones industrial average gave up 0.4% also. Nasdaq and NYSE volume was tracking slightly higher than...
AMBA: 46.33 (-1.64), GPRO: 60.52 (+0.47), CBST: 96.31 (+0.04), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), UTHR: 129.37 (-1.86), MCD: 90.62 (-0.35), REGN: 416.44 (-7.91), CELG: 114.49 (-2.25)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.47 (+0.01), GILD: 104.13 (-0.18), UTHR: 129.37 (-1.86), GSK: 42.42 (-0.93), ARNA: 3.91 (-0.18)
Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 2:10PM CST
Actelion Ltd. (ALIOF) submitted a centralized marketing authorization application to the European Medicines Agency for its PAH candidate, Uptravi (selexipag).
BIIB: 344.49 (+2.16), UTHR: 129.37 (-1.86)
Stock Market Today: Top Biotech Is Near Buy Point
at Investor's Business Daily - Wed Nov 26, 4:40PM CST
Many leading stocks have risen out of buying range since a new market uptrend began last month, but a number are still working on bases. United Therapeutics (UTHR), which develops treatments for cardiovascular and infectious diseases as well as for...
UTHR: 129.37 (-1.86), GIII: 94.76 (-0.60), CAR: 58.65 (-3.55), CP: 176.41 (+1.71)
United Therapeutics Earnings In Retrospect: Down 3.9% in the Last 20 Days (UTHR)
Comtex SmarTrend(R) - Mon Nov 17, 3:24PM CST
20 days ago, on October 28th, 2014, United Therapeutics (NASDAQ:UTHR) reported its earnings. Analysts, on average, expected earnings of $2.75 per share on sales of $335.1 million. The company actually reported EPS of $3.91 on sales of $330.0 million, beating EPS estimates by $1.16 and missing revenue estimates by $5.2 million. Since the company's report, shares of United Therapeutics have fallen from $130.49 to $125.43, representing a loss of 3.9% in the past 20 days.
UTHR: 129.37 (-1.86)
United Therapeutics appoints Professor Katherine J. Klein to board
M2 - Thu Nov 13, 7:08AM CST
Biotechnology company United Therapeutics (NasdaqGS:UTHR) stated on Thursday that Professor Katherine J. Klein, PhD has been elected as an independent director to its board of directors with effect from 11 November 2014.
UTHR: 129.37 (-1.86)
Professor Katherine J. Klein Joins The United Therapeutics Corporation Board Of Directors
PR Newswire - Thu Nov 13, 5:00AM CST
United Therapeutics Corporation (NASDAQ: UTHR) announced today the appointment of Professor Katherine J. Klein, Ph.D., of The Wharton School of the University of Pennsylvania to its Board of Directors as an independent director. The appointment is effective as of November 11, 2014.
UTHR: 129.37 (-1.86), SCHW: 28.75 (-0.93)
United Therapeutics Earnings In Retrospect: Down 4.8% in the Last 13 Days (UTHR)
Comtex SmarTrend(R) - Mon Nov 10, 12:57PM CST
When United Therapeutics (NASDAQ:UTHR) reported earnings a week ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $2.75 on sales of $335.1 million. United Therapeutics actually reported earnings of $3.91 per share on sales of $330.0 million, beating EPS estimates by $1.16 and missing revenue estimates by $5.2 million. Shares of United Therapeutics have slipped from $130.49 to $124.21, representing a loss of 4.8%, since the company reported earnings 13 days ago.
UTHR: 129.37 (-1.86)
Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 43.69 (-0.77), WMGI: 28.30 (-0.10), CFN: 58.86 (-0.14), UTHR: 129.37 (-1.86), RCPT: 120.08 (-1.38), WMGIZ: 4.22 (-0.18)
Mid-Atlantic Claims $8.5 Billion Slice of $62 Billion North American Life Science Capital/MRO Investment Pie, an Industrial Info News Alert
Marketwired - Fri Oct 31, 5:15AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- There are more than 1,400 active reported Pharmaceutical-Biotech capital and maintenance (MRO) projects in North America, representing a total investment value (TIV) of nearly $62 billion. According to a recent analysis of Industrial Info's Pharmaceutical-Biotech Industry database, the Mid-Atlantic region is at the top of that investment, accounting for an $8.5 billion portion of that spending divided over 176 projects.
UTHR: 129.37 (-1.86)
Apple CEO publicly acknowledges that he's gay
By MAE ANDERSON - AP - Thu Oct 30, 6:59PM CDT
NEW YORK (AP) — Apple CEO Tim Cook's declaration that he's "proud to be gay" wasn't exactly news in Silicon Valley, where his sexual orientation was no secret. But advocates say that given Apple's immense reach and visibility, his coming-out could help change attitudes in workplaces across America.
UTHR: 129.37 (-1.86), AEO: 13.21 (+0.30), AAPL: 109.73 (-1.89)
United Therapeutics Sells Off On Good News - Why I Bought That Dip
DoctoRx - Seeking Alpha - Thu Oct 30, 2:52PM CDT
Background : The smallish biotech/biopharma company United Therapeutics (NASDAQ: UTHR ) is a favorite of mine on its own merits and as a takeover play. The company has a steadfast focus on the fatal orphan disease known as PAH (pulmonary arterial...
MDT: 72.52 (-1.25), GILD: 104.13 (-0.18), UTHR: 129.37 (-1.86), SUPN: 8.72 (+0.02), AMGN: 164.53 (-1.55), GSK: 42.42 (-0.93)
United Therapeutics Falls on Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:02AM CDT
United Therapeutics Corporation (UTHR) incurred a third-quarter loss of 53 cents per share, missing the Zacks Consensus Estimate by a wide margin.
LCI: 43.58 (-0.46), MDT: 72.52 (-1.25), UTHR: 129.37 (-1.86), NVS: 93.52 (-0.82)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 15.94 (+0.74), BIIB: 344.49 (+2.16), AMRN: 1.08 (+0.04), UTHR: 129.37 (-1.86), NLNK: 35.69 (+0.27)
SmarTrend Watching for Potential Rebound in Shares of United Therapeutics After 2.00% Loss
Comtex SmarTrend(R) - Tue Oct 28, 5:19PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $121.16 to a high of $131.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $127.76 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 129.37 (-1.86)
Watch for United Therapeutics to Potentially Rebound After Falling 2.00% Yesterday
Comtex SmarTrend(R) - Tue Oct 28, 5:18PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $121.16 to a high of $131.00. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $127.76 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 129.37 (-1.86)
